Key points are not available for this paper at this time.
This retrospective case series compares vitiligo resulting from immune checkpoint inhibitor (ICI) therapy vs preexisting vitiligo among patients receiving ICI treatment for cancer.
Starace et al. (Mon,) studied this question.